Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and lowers the price target from $1200 to $1050.
Wells Fargo Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1050
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.